Floatz logo

NOS

Parkinson Disease

University of PennsylvaniaSmall moleculeEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

255 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

NOS is also rated in:

Cardiac AmyloidosisDormant
C
Indicative ·
39 / 100
View asset →
Alzheimer diseaseDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →